Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study.

Fiche publication

Date publication

juin 2023

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr HERVIEU Alice

Tous les auteurs :
Le Cesne A, Chevreau C, Perrin C, Italiano A, Hervieu A, Blay JY, Piperno-Neumann S, Saada-Bouzid E, Bertucci F, Firmin N, Kalbacher E, Narciso B, Schiffler C, Yara S, Jimenez M, Bouvier C, Vidal V, Chabaud S, Duffaud F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37285716

Résumé

REGOBONE multicohort study explored the efficacy and safety of regorafenib for patients with advanced bone sarcomas; this report details the cohort of patients with relapsed advanced or metastatic chordoma.